Parekh Palak, Rao K V K
Chemical Carcinogenesis Group, Cancer Research Institute, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai 410 208, India.
Cell Biol Int. 2007 Jan;31(1):35-43. doi: 10.1016/j.cellbi.2006.09.005. Epub 2006 Sep 10.
Hepatocellular carcinoma (HCC) is a multi-factorial and multi-step process. However, the molecular mechanisms, which play a pivotal role during progressive development of HCC, are not known. Accordingly Sprague-Dawley rats were administered diethylnitrosamine (DEN) for one to three months in order to understand the molecular alterations during progressive development of liver tumor. In this study involvement of G1/S regulatory proteins, MAP kinases and cell survival factors were analyzed using RT-PCR, western blotting and in vitro kinase assays. The data showed overexpression of cyclin D1 and increased expression and activation of ERK1/2, p38 kinase and JNK1/2 with progression of tumor suggesting that MAP kinases play an important role during tumorigenesis. These molecular alterations were supported by Akt upregulation and increase in the levels of inactive GSK3beta with progression of liver tumor. Further, p21-actived kinase1 (Pak1) was found to be upregulated with tumor progression, which is a novel observation during progressive liver carcinogenesis. These results indicate that elevated levels of all the three MAP kinases (ERK1/2, p38 and JNK1/2), Akt/GSK3beta and Pak1 are associated with cyclin D1 upregulation, which helps in the disruption of the G1/S regulatory point of the cell cycle and leads to abnormal cell proliferation during progressive hepatocarcinogenesis.
肝细胞癌(HCC)是一个多因素、多步骤的过程。然而,在HCC进展过程中起关键作用的分子机制尚不清楚。因此,为了了解肝肿瘤进展过程中的分子变化,对Sprague-Dawley大鼠给予二乙基亚硝胺(DEN)1至3个月。在本研究中,使用逆转录聚合酶链反应(RT-PCR)、蛋白质免疫印迹法和体外激酶测定法分析了G1/S调节蛋白、丝裂原活化蛋白激酶(MAP激酶)和细胞存活因子的参与情况。数据显示,随着肿瘤进展,细胞周期蛋白D1过表达,细胞外信号调节激酶1/2(ERK1/2)、p38激酶和应激活化蛋白激酶1/2(JNK1/2)的表达和活化增加,表明MAP激酶在肿瘤发生过程中起重要作用。这些分子变化得到了Akt上调以及随着肝肿瘤进展无活性糖原合成酶激酶3β(GSK3β)水平增加的支持。此外,发现p21活化激酶1(Pak1)随着肿瘤进展而上调,这是肝致癌过程中的一个新发现。这些结果表明,三种MAP激酶(ERK1/2、p38和JNK1/2)、Akt/GSK3β和Pak1水平的升高与细胞周期蛋白D1上调相关,这有助于破坏细胞周期的G1/S调节点,并导致进行性肝癌发生过程中的异常细胞增殖。